Roche’s Tecentriq, Avastin combo improves OS in unresectable HCC

This article was originally published here

The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 501 patients with unresectable HCC, who did not receive prior systemic therapy. Data

The post Roche’s Tecentriq, Avastin combo improves OS in unresectable HCC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply